Government
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 11, 2020.
Eli Lilly is moving quickly to get a newly-approved precision oncology treatment, Retevmo, for certain lung and thyroid cancers into the hands of patients.
The new at-home saliva self-collection assay allows for broader screening than the standard and uncomfortable method using nose and throat swabs at a healthcare facility or testing location that requires a physical interaction with a healthcare professional.
Despite the COVID-19 pandemic, the U.S. Food and Drug Administration has managed to stay fairly on track in terms of evaluating new drug and supplemental new drug applications. Here’s a look at what’s on the schedule for the next two weeks.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.
To date, 10 plasma companies globally have joined the CoVIg-19 Plasma Alliance, founded to accelerate development of a plasma-derived hyperimmune globulin therapy against COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.
Developed by Novartis, the drug, Tabrecta, is designed for a type of NSCLC that has spread to other parts of the body and cannot be removed by surgery.
The CD19-directed chimeric antigen receptor (CAR) T cell therapy is a treatment for adults with relapsed or refractory large B-cell lymphoma after at least two prior therapies.
The drug can potentially reduce the risk of cardiovascular death and hospitalization for heart failure.
PRESS RELEASES